Iodine-131 metaiodobenzylguanidine (I-31 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: Current problems, critical issues and presentation of a sample case

M. R. Castellani, C. Aktolun, R. Buzzoni, E. Seregni, C. Chiesa, M. Maccauro, G. L. Aliberti, C. Vellani, A. Lorenzoni, E. Bombardieri

Research output: Contribution to journalArticlepeer-review

Abstract

Iodine-131 metaiodobenzylguanidine (I-131 MIBG) has been used for the diagnosis and treatment of malignant pheochromocytomas (PHEO) and paragangliomas (PGL) since 1980's. Despite increasing amount of experience with iodine-131 (I-131) MIBG therapy, many important questions still exist. In this article, we will discuss the current problems learned from clinical experience in diagnosis and therapy of PHEO/PGL with I-131 MIBG, and present a sample case to emphasize the critical aspects for an optimal treatment strategy.

Original languageEnglish
Pages (from-to)146-152
Number of pages7
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume57
Issue number2
Publication statusPublished - Jun 2013

Keywords

  • Adrenal glands
  • Neural crest tumor
  • Neuroendocrine tumors
  • Positron emission tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Iodine-131 metaiodobenzylguanidine (I-31 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: Current problems, critical issues and presentation of a sample case'. Together they form a unique fingerprint.

Cite this